We are live on ! Find out more
DSGN icon

Design Therapeutics

50 hedge funds and large institutions have $546M invested in Design Therapeutics in 2021 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

16% more funds holding

Funds holding: 4350 (+7)

2.18% more ownership

Funds ownership: 47.87%50.05% (+2.2%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

28% less capital invested

Capital invested by funds: $755M → $546M (-$209M)

Holders
50
Holders Change
+7
Holders Change %
+16.28%
% of All Funds
0.87%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
18
Increased
13
Reduced
6
Closed
11
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
51
Millennium Management
New York
-$7.57M -253,037 Closed
Alyeska Investment Group
52
Alyeska Investment Group
Illinois
-$1.5M -50,000 Closed
Balyasny Asset Management
53
Balyasny Asset Management
Illinois
-$1.29M -43,250 Closed
OMC
54
Old Mission Capital
Illinois
-$798K -26,700 Closed
Squarepoint
55
Squarepoint
New York
-$702K -23,493 Closed
AGM
56
Alpine Global Management
New York
-$401K -13,405 Closed
MS
57
Maven Securities
Jersey
-$299K -10,000 Closed
PHK
58
Point72 Hong Kong
Hong Kong
-$248K -8,304 Closed
TRSOTSOK
59
Teachers Retirement System of the State of Kentucky
Kentucky
-$248K -8,300 Closed
SWM
60
Spire Wealth Management
Virginia
-$27K -900 Closed
FMT
61
First Mercantile Trust
Tennessee
-$21K -700 Closed

DSGN Hedge Fund Activity: Q2 2021 in Review

50 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q2 2021, worth a combined $546M — down 28% from $755M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new DSGN positions and 11 closed out — a net gain of 7 holders — while 13 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $27.3M. The largest seller was Millennium Management, exiting entirely with an estimated $7.57M sold.

  • 50 institutional investors held Design Therapeutics (DSGN) as of Q2 2021, up from 43 in Q1 2021.
  • Funds reported $546M of Design Therapeutics stock for Q2 2021, down 28% quarter-over-quarter.
  • 18 funds opened new Design Therapeutics positions in Q2 2021 and 11 closed out, a net change of +7 holders.
  • The largest Design Therapeutics buyer in Q2 2021 was Vanguard Group, an estimated $27.3M added.
  • The largest Design Therapeutics seller in Q2 2021 was Millennium Management, an estimated $7.57M sold.

Based on aggregated 13F filings for Q2 2021.